Clinical Trials Logo

Clinical Trial Summary

Vitiligo vulgaris is an autoimmune disorder that causes loss of pigmentation over the skin, hair and mucous membranes (e.g. lips, nose, genitals). While genes have been identified that are thought to be required for development of vitiligo, only 5-10% of relatives develop disease. The triggers for disease onset have not yet been identified. The intent of this study is to research trends in laboratory data, social and medical history that may be contributory to vitiligo onset, location of disease, course of illness and response to therapy.


Clinical Trial Description

Patients who participate in this study will be asked to complete a survey and have blood/ laboratory testing performed that relates or may relate to the diagnosis of vitiligo. ;


Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT01206374
Study type Observational
Source St. Luke's-Roosevelt Hospital Center
Contact
Status Completed
Phase N/A
Start date August 2010
Completion date September 2014

See also
  Status Clinical Trial Phase
Completed NCT00907062 - Ginkgo Biloba for the Treatment of Vitiligo Vulgaris in Adolescents Phase 1
Completed NCT00372307 - Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo Vulgaris Phase 2
Completed NCT01401374 - Online Health Survey of Patients With Vitiligo Vulgaris/ Online Survey of Pediatric Patients With Vitiligo N/A
Not yet recruiting NCT03234673 - The Effect of Fractional Co2 Laser Either With Tacrolimus, Calcipotriol or NB-UVB in Stable Generalized Vitiligo Phase 1